Background

The incidence of systemic infections by Saccharomyces cerevisiae has increased in recent years, especially among immunocompromised patients. Amphotericin B, voriconazole or echinocandins have been used with favorable outcome against systemic infections by this fungus. However, clinical experience is limited and no in vivo studies have been conducted.

Aims

We evaluated the in vitro activity of nine antifungal compounds against S. cerevisiae and the in vivo efficacy of those three antifungals showing the highest in vitro activity by using a murine model of systemic infection.

Methods

Minimal inhibitory concentrations (MICs) were determined by the microdilution method against three strains of S. cerevisiae. After intravenous infection with 5 × 10⁷ CFUs, animals received liposomal amphotericin B (5 mg/kg), voriconazole (25 mg/kg) or anidulafungin (5 mg/kg). Treatment efficacy was assessed by determining of CFUs/g in liver, kidney, brain, lung and spleen.

Results

5-Fluorocytosine was the most in vitro active compound followed by amphotericin B, voriconazole and anidulafungin. The in vivo study showed that liposomal amphotericin B was the most effective drug driving highest fungal clearance.

Conclusions

All treatments reduced the fungal load in comparison to the control group, being liposomal amphotericin B the most effective drug followed by anidulafungin and finally voriconazole.

中文翻译：

---

酿酒酵母的抗真菌药性和在散布感染的鼠模型中的治疗。

背景

近年来，酿酒酵母（Saccharomyces cerevisiae）全身感染的发生率有所增加，尤其是在免疫功能低下的患者中。已经使用两性霉素B，伏立康唑或棘霉素，对这种真菌的全身感染有良好的效果。但是，临床经验有限，并且尚未进行体内研究。

目的

我们评估了在体外的对9个抗真菌化合物活性S. 酵母和体内这三个抗真菌剂的功效显示出最高的体外通过使用全身性感染的小鼠模型的活性。

方法

通过微量稀释法确定了针对三种酿酒酵母的最小抑制浓度（MIC）。用5×10 ⁷ CFU静脉感染后，动物接受脂质体两性霉素B（5 mg / kg），伏立康唑（25 mg / kg）或阿尼芬净（5 mg / kg）。通过确定肝，肾，脑，肺和脾中的CFU / g评估治疗效果。

结果

5-氟胞嘧啶是体外活性最高的化合物，其次是两性霉素B，伏立康唑和阿尼芬净。该体内研究表明霉素B脂质体是最有效的药后驾驶的最高真菌间隙。

结论

与对照组相比，所有治疗均降低了真菌负荷，脂质体两性霉素B是最有效的药物，其次是阿尼芬净，最后是伏立康唑。